Avenda Health’s iQuest Prostate 3D Cancer Mapping Platform Cleared

The FDA has granted 510(k) clearance to Avenda Health’s iQuest platform which provides 3D visualizations of prostate tumors.

The mapping software uses deep learning algorithms to analyze the patient’s diagnostic information to create a detailed map of the cancer within the prostate, allowing treatment of the tumor only instead of the entire organ.

The platform showed a sensitivity of more than 98 percent in finding the extent of cancer in patients who have intermediate-risk disease — the most frequently treated form of prostate cancer.